Literature DB >> 15966284

Quality assurance in cervical smears: 100% rapid rescreening vs. 10% random rescreening.

Rita Goreti Amaral1, Luiz Carlos Zeferino, Ellen Hardy, Maria Cristina do Amaral Westin, Edson Zangiacomi Martinez, Eliana Borin Montemor.   

Abstract

OBJECTIVE: To compare 100% rapid rescreening of cervical smears with 10% random rescreening as a method of quality assurance. STUDY
DESIGN: A total of 5215 smears, randomly selected from smears reported as negative by cytotechnologists during routine screening, underwent 100% rapid rescreening by senior cytotechnologists. Ten percent of these smears, selected at random, were rescreened by other senior cytotechnologists. The gold standard was defined by cytopathologists, who rescreened all 5215 smears. After excluding unsatisfactory smears detected by cytopathologists, 4271 were included in the analysis.
RESULTS: The 100% rapid rescreening method identified 69.9%, 95.7% and 100%, respectively, of atypical squamous cells of undetermined significance, low grade squamous intraepithelial lesion and high grade squamous intraepithelial lesion cases reported by the cytopathologists. The 100% rapid rescreening method showed a sensitivity of 73.5% and specificity of 98.6%. The 10% rescreening method showed sensitivity of 40.9% and specificity of 98.8%.
CONCLUSION: One hundred percent rapid rescreening is an efficient method of internal quality assurance in cervical smear diagnosis. It can reduce the false negative rate and therefore can provide greater certainty to women who have received negative results. Well-trained cytotechnologists are able to identify abnormal smears in 1-minute rapid rescreening.

Entities:  

Mesh:

Year:  2005        PMID: 15966284     DOI: 10.1159/000326144

Source DB:  PubMed          Journal:  Acta Cytol        ISSN: 0001-5547            Impact factor:   2.319


  1 in total

1.  Informatics applied to cytology.

Authors:  Liron Pantanowitz; Maryanne Hornish; Robert A Goulart
Journal:  Cytojournal       Date:  2008-12-29       Impact factor: 2.091

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.